Choose Your Country or Region

E3 Ligase

Isoform-selective Products

CRBN

Signaling Pathway

E3 Ligase Products

All (53)
E3 Ligase Inhibitors (29)
E3 Ligase Activator (1)
E3 Ligase Antagonists (2)
E3 Ligase Modulators (4)
New E3 Ligase Products

Catalog No.	Product Name	Information	Product Use Citations
S1029	Lenalidomide	Lenalidomide is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.	Signal Transduct Target Ther, 2025, 10(1):29 Nat Commun, 2025, 16(1):3800 Cell Rep Med, 2025, S2666-3791(25)00102-8
S1567	Pomalidomide	Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.	Cell Rep Med, 2025, S2666-3791(25)00102-8 Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136 Biomed Pharmacother, 2025, 184:117878
S1061	Nutlin-3	Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.	Cancer Discov, 2025, 15(1):69-82 Biomed Rep, 2025, 22(4):65 Nat Biotechnol, 2024, 10.1038/s41587-024-02172-9
S2754	Xevinapant (AT406)	Xevinapant (AT406, ARRY-334543, Debio1143, SM-406) is a potent Smac mimetic and an antagonist of IAP (inhibitor of apoptosis protein via E3 ubiquitin ligase), binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with K_i of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide. Phase 1.	Nat Commun, 2025, 16(1):2572 Cell Death Dis, 2024, 15(11):855 Pharmaceuticals (Basel), 2024, 17(11)1529
S1193	Thalidomide	Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1.	Biomed Pharmacother, 2025, 184:117878 Nat Commun, 2024, 15(1):9195 Cell Rep Med, 2024, 5(10):101752
S1172	Serdemetan (JNJ-26854165)	Serdemetan (JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.	Elife, 2025, 14e75393 Signal Transduct Target Ther, 2022, 7(1):97 iScience, 2021, 24(9):103080
S2225	TAME	Tosyl-L-Arginine Methyl Ester (TAME) is an APC inhibitor.	Dev Cell, 2023, 58(3):192-210.e11 J Pers Med, 2022, 12(2)258 Hum Cell, 2022, 10.1007/s13577-022-00671-y
S2781	RITA	RITA induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.	Cell Death Discov, 2024, 10(1):381 J Cancer, 2023, 14(2):200-218 Theranostics, 2022, 12(9):4110-4126
S8652	Skp2 inhibitor C1 (SKPin C1)	Skp2 inhibitor C1 (SKPin C1) is a specific and selective small-molecule inhibitor of Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.	Cell Rep Med, 2025, S2666-3791(25)00231-9 The Journal of Clinical Investigation, 2022-, -Volume 132, Issue 24 J Clin Invest, 2022, e153943
S2678	NSC 207895	NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.	PLoS One, 2024, 19(1):e0295629 Front Oncol, 2021, 11:582511 Genes Dev, 2020, 34(7-8):526-543
S8760	Iberdomide (CC220)	Iberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.	Cell Rep Med, 2025, S2666-3791(25)00102-8 Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136 Cancers (Basel), 2025, 17(3)461
S5315	PRT4165	PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro.	Nat Commun, 2023, 10.1038/s41467-023-42930-y Leukemia, 2021, 10.1038/s41375-021-01121-8 Leukemia, 2021, 10.1038/s41375-021-01121-8
S7892	Avadomide (CC-122)	Avadomide (CC-122), a new chemical entity termed pleiotropic pathway modifier, is a novel agent for Diffuse large B-cell lymphoma(DLBCL) with antitumor and immunomodulatory activity. Its molecular target is the protein cereblon (CRBN), a substrate receptor of the cullin ring E3 ubiquitin ligase complex CRL4^CRBN.	bioRxiv, 2024, 10.1101/2024.01.28.577572 Cell Chem Biol, 2022, S2451-9456(22)00204-5 Leukemia, 2021, 35(5):1330-1343
S9605	Apcin	Apcin (APC inhibitor) is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C) that binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates.	Theranostics, 2025, 15(8):3439-3461 Cell Mol Biol Lett, 2025, 30(1):29 Exp Hematol Oncol, 2023, 12(1):28
S9724	SZL P1-41	SZL P1-41 (compound #25) is a specific inhibitor of S-phase kinase-associated protein 2 (Skp2) that indeed binds to Skp2, prevents Skp2-Skp1 interaction and inhibits Skp2 SCF E3 ligase activity, which consequently suppresses survival of cancer cells and cancer stem cells. SZL P1-41 causes higher apoptosis rates in cancer cells.	J Immunother Cancer, 2024, 12(12)e009444 Cell Death Discov, 2023, 9(1):364 Cell Death Discov, 2023, 9(1):364
S8975	Mezigdomide (CC-92480)	Mezigdomide (CC-92480) is a novel protein degrader and a cereblon E3 ligase modulator (CELMoD) that has anti-myeloma activity.	Nat Commun, 2024, 15(1):8885 Mol Cancer Ther, 2023, 22(5):659-666 Mol Cancer Ther, 2023, 22(5):659-666
S2881	Homo-PROTAC cereblon degrader 1	Homo-PROTAC cereblon degrader 1 (OUN20985) is a potent and efficient cereblon (CRBN) degrader with minimal effects on IKZF1 and IKZF3.	Antimicrob Agents Chemother, 2025, 69(1):e0117224 Eur J Immunol, 2021, 10.1002/eji.202149269
F0528^New	Ubiquitin (linkage-specific Lys 63) Rabbit mAb	K63-linkage Specific Polyubiquitin,Ubiquitin (linkage-specific K63),Ub-K63
F1454	UHRF1 Rabbit mAb
F2194^New	Cullin 1/CUL-1 Rabbit mAb	CUL1,CUL-1,Cullin 1,Cullin 1/CUL-1
F0313	Ubiquityl-Histone H2A (Lys119) Rabbit mAb	ubiquityl-Histone H2A,Ubiquityl-Histone H2A (Lys119)
F1436	Skp1 Rabbit mAb	Skp1 p19
F1352	RNF40 Rabbit mAb
F1308	Rad18 Rabbit mAb
F1418	Ring1A Rabbit mAb
F1516^New	PIAS3 Rabbit mAb
S4925	SMER3	SMER3, the small-molecule enhancer of rapamycin (SMER), is an inhibitor of the Skp1-Cullin-F-box (SCF)^Met30 ubiquitin ligase with IC50 of 51 nM.
F1233^New	KLHL12 Mouse mAb
E1427	MRT-2359	MRT-2359 is a potent degrader of GSPT1. It exhibits anti-tumor activity in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.
E1957^New	NX-1607	NX-1607 (Cbl-b-IN-3) is an oral inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), which is an E3 ubiquitin ligase and a key regulator of T, NK, and dendritic cell activation and suppresses their anti-tumor functions. NX-1607 enhances antigen recall, reduces T cell exhaustion, and increases cytokine production in response to T cell receptor stimulation, thereby counteracting suppressive signals from the tumor microenvironment.
S8300	CC-885	CC-885 is a novel cereblon (CRBN) modulator. CC-885 selectively promotes CRBN- and p97-dependent PLK1 ubiquitination and degradation.	Sci Rep, 2025, 15(1):2384
S9889	dCBP-1	dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP by hijacking the E3 ubiquitin ligase CRBN, also is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drives MYC oncogene expression.
S0322	BC-1215	BC-1215 is an inhibitor of F-box protein 3 (Fbxo3, a ubiquitin E3 ligase component) with IC50 of 0.9 μg/mL and LC50 of 87 μg/ml for IL-1β release. BC-1215 inhibits the Fbxo3-TRAF activation pathway by destabilizing TRAF1-6.
E5844^New	NSC2805	NSC2805 is a potent inhibitor of WWP2 ubiquitin ligase with an IC50 of 0.38 μM. It is used in cancer research for studying WWP2-associated pathways.
S9832	CC-90009	CC-90009 is a novel cereblon (CRBN) E3 ligase modulator and specifically targets GSPT1 (G1 to S phase transition 1) for proteasomal degradation.
E1847^New	GBD-9	GBD-9 is a double-mechanism efficient degrader of BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). GBD-9 acts both as a PROTAC molecule to induce the degradation of BTK and as a molecular glue to degrade GSPT1.It exhibits anti-proliferative effects, inhibiting cancer cell survival.
S0095	VL285	VL285 is a potent VHL ligand that degrades HaloTag7 fusion proteins. Cotreatment with excess VL285, the core VHL ligand from which HaloPROTAC3 is derived, is able to significantly reduce HaloPROTAC3 mediated activity to 50% degradation.	Int J Mol Sci, 2024, 25(16)8984 Molecules, 2024, 29(2)482
S0097	(S,R,S)-AHPC (MDK7526)	(S,R,S)-AHPC (MDK7526, VH032-NH2, VHL ligand 1) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC is potential useful for the targeted degradation of the androgen receptor. (S,R,S)-AHPC can be connected to the ligand for protein such as BCR-ABL1 by a linker to form PROTACs such as GMB-475. GMB-475 induces the degradation of BCR-ABL1 with IC50 of 1.11 μM in Ba/F3 cells.
S0345	Smurf1-IN-A01	Smurf1-IN-A01 can inhibit Smurf1-mediated Smad1/5 degradation and accelerate BMP-2 signal responsiveness with a Kd of 3.664 nM.
S3502	(S,R,S)-AHPC-PEG4-NH2 hydrochloride	(S,R,S)-AHPC-PEG4-NH2 hydrochloride (VH032-PEG4-NH2 hydrochloride, VHL Ligand-Linker Conjugates 4 hydrochloride, E3 ligase Ligand-Linker Conjugates 7) is a PROTAC E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker.
S8449	VH298	VH298 is a potent VHL (Von Hippel-Lindau, the E3 ligase) inhibitor that stabilizes HIF-α. VH298 blocks the VHL:HIF-α interaction with Kd of 90 nM in isothermal titration calorimetry (ITC) and 80 nM in a competitive fluorescence polarization assay. VH-298 can be used in PROTAC technology.	Cell Rep, 2025, 44(6):115800 Eur J Med Chem, 2024, 268:116202
S1015	Thalidomide-OH	Thalidomide-OH (Cereblon ligand 2, E3 ligase Ligand 2) is a presumed hydroxylated thalidomide metabolite, with weak antiangiogenic activity (the average inhibition rate of vessel density was 14% in 100 μg), also can be applicable to the recruitment of CRBN protein.
E1300	SJ6986	SJ6986 is a CRBN modulator and specifically degrades GSPT1/2, with a DC50 of 2.1 nM (Dmax 99%) for GSPT1.
E0071	MuRF1-IN-1	MuRF1-IN-1 is a muscle ring finger protein-1 (MuRF1) inhibitor that attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia.
E1937	PT-179	PT-179, an orthogonal Thalidomide derivative targets cereblon without causing off-target degradation effects. PT-179 specifically binds CRBN, forms a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediates the degradation of the tagged protein.
S8888	GMB-475	GMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.
S8979	THAL-SNS-032	THAL-SNS-032 is a selective Cyclin-dependent kinase 9 (CDK9) degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to that binds the E3 ubiquitin ligase Cereblon (CRBN).	Gastroenterology, 2024, S0016-5085(24)00062-3
E5839^New	OICR-8268	OICR-8268 is a potent, reversible and in-cell active DCAF1 ligand. It significantly binds to DCAF1 WDR domain with an Kd value of 38 nM. It serves as a promising starting point for developing chemical handles for DCAF1-based PROTACs targeting selective protein degradation as well as cancer therapeutics.
E5877^New	LYG-409	LYG-409 is a potent, selective, and orally bioavailable degrader of GSPT1, with a DC50 of 7.87 nM. It exhibits strong antiproliferative activity in KG-1 cells with an IC50 of 9.50 nM and demonstrates significant antitumor efficacy in vivo in models of acute myeloid leukemia and prostate cancer.
E0351	NSC232003	NSC232003 is a highly potent and cell-permeable UHRF1 inhibitor that binds to the 5mC binding pocket of the SRA domain of UHRF1. NSC232003 modulates DNA methylation in a cellular context.
E1678	SPOP-i-6lc	SPOP-i-6lc is a selective speckle-type POZ protein (SPOP) E3 ubiquitin ligase inhibitor with IC50 of 2.1 μM and 3.5 μM, in A498 and OS-RC-2 cell lines, respectively. In vitro, It suppresses viability and proliferation of A498 and OS-RC-2 kidney cancer cell lines.
S6794	Thalidomide-O-COOH (Cereblon ligand 3)	Thalidomide-O-COOH (Cereblon ligand 3, E3 ligase Ligand 3), a Thalidomide-based Cereblon (CRBN) ligand, is used in the recruitment of CRBN protein. Thalidomide-O-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs (Proteolysis Targeting Chimera).
E1087	5-amino-2,4-dimethylpyridine (5A-DMP)	5-amino-2,4-dimethylpyridine (5A-DMP) is a novel tandem Tudor domain (TTD)-binding compound that inhibits the full-length UHRF1:LIG1 interaction in Xenopus egg extracts.
S1029	Lenalidomide	Lenalidomide is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.	Signal Transduct Target Ther, 2025, 10(1):29 Nat Commun, 2025, 16(1):3800 Cell Rep Med, 2025, S2666-3791(25)00102-8
S1567	Pomalidomide	Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.	Cell Rep Med, 2025, S2666-3791(25)00102-8 Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136 Biomed Pharmacother, 2025, 184:117878
S2754	Xevinapant (AT406)	Xevinapant (AT406, ARRY-334543, Debio1143, SM-406) is a potent Smac mimetic and an antagonist of IAP (inhibitor of apoptosis protein via E3 ubiquitin ligase), binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with K_i of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide. Phase 1.	Nat Commun, 2025, 16(1):2572 Cell Death Dis, 2024, 15(11):855 Pharmaceuticals (Basel), 2024, 17(11)1529
S1193	Thalidomide	Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1.	Biomed Pharmacother, 2025, 184:117878 Nat Commun, 2024, 15(1):9195 Cell Rep Med, 2024, 5(10):101752
S2225	TAME	Tosyl-L-Arginine Methyl Ester (TAME) is an APC inhibitor.	Dev Cell, 2023, 58(3):192-210.e11 J Pers Med, 2022, 12(2)258 Hum Cell, 2022, 10.1007/s13577-022-00671-y
S2781	RITA	RITA induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.	Cell Death Discov, 2024, 10(1):381 J Cancer, 2023, 14(2):200-218 Theranostics, 2022, 12(9):4110-4126
S8652	Skp2 inhibitor C1 (SKPin C1)	Skp2 inhibitor C1 (SKPin C1) is a specific and selective small-molecule inhibitor of Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.	Cell Rep Med, 2025, S2666-3791(25)00231-9 The Journal of Clinical Investigation, 2022-, -Volume 132, Issue 24 J Clin Invest, 2022, e153943
S8760	Iberdomide (CC220)	Iberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.	Cell Rep Med, 2025, S2666-3791(25)00102-8 Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136 Cancers (Basel), 2025, 17(3)461
S5315	PRT4165	PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro.	Nat Commun, 2023, 10.1038/s41467-023-42930-y Leukemia, 2021, 10.1038/s41375-021-01121-8 Leukemia, 2021, 10.1038/s41375-021-01121-8
S7892	Avadomide (CC-122)	Avadomide (CC-122), a new chemical entity termed pleiotropic pathway modifier, is a novel agent for Diffuse large B-cell lymphoma(DLBCL) with antitumor and immunomodulatory activity. Its molecular target is the protein cereblon (CRBN), a substrate receptor of the cullin ring E3 ubiquitin ligase complex CRL4^CRBN.	bioRxiv, 2024, 10.1101/2024.01.28.577572 Cell Chem Biol, 2022, S2451-9456(22)00204-5 Leukemia, 2021, 35(5):1330-1343
S9605	Apcin	Apcin (APC inhibitor) is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C) that binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates.	Theranostics, 2025, 15(8):3439-3461 Cell Mol Biol Lett, 2025, 30(1):29 Exp Hematol Oncol, 2023, 12(1):28
S9724	SZL P1-41	SZL P1-41 (compound #25) is a specific inhibitor of S-phase kinase-associated protein 2 (Skp2) that indeed binds to Skp2, prevents Skp2-Skp1 interaction and inhibits Skp2 SCF E3 ligase activity, which consequently suppresses survival of cancer cells and cancer stem cells. SZL P1-41 causes higher apoptosis rates in cancer cells.	J Immunother Cancer, 2024, 12(12)e009444 Cell Death Discov, 2023, 9(1):364 Cell Death Discov, 2023, 9(1):364
S2881	Homo-PROTAC cereblon degrader 1	Homo-PROTAC cereblon degrader 1 (OUN20985) is a potent and efficient cereblon (CRBN) degrader with minimal effects on IKZF1 and IKZF3.	Antimicrob Agents Chemother, 2025, 69(1):e0117224 Eur J Immunol, 2021, 10.1002/eji.202149269
S4925	SMER3	SMER3, the small-molecule enhancer of rapamycin (SMER), is an inhibitor of the Skp1-Cullin-F-box (SCF)^Met30 ubiquitin ligase with IC50 of 51 nM.
E1957^New	NX-1607	NX-1607 (Cbl-b-IN-3) is an oral inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), which is an E3 ubiquitin ligase and a key regulator of T, NK, and dendritic cell activation and suppresses their anti-tumor functions. NX-1607 enhances antigen recall, reduces T cell exhaustion, and increases cytokine production in response to T cell receptor stimulation, thereby counteracting suppressive signals from the tumor microenvironment.
S9889	dCBP-1	dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP by hijacking the E3 ubiquitin ligase CRBN, also is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drives MYC oncogene expression.
S0322	BC-1215	BC-1215 is an inhibitor of F-box protein 3 (Fbxo3, a ubiquitin E3 ligase component) with IC50 of 0.9 μg/mL and LC50 of 87 μg/ml for IL-1β release. BC-1215 inhibits the Fbxo3-TRAF activation pathway by destabilizing TRAF1-6.
E5844^New	NSC2805	NSC2805 is a potent inhibitor of WWP2 ubiquitin ligase with an IC50 of 0.38 μM. It is used in cancer research for studying WWP2-associated pathways.
S9832	CC-90009	CC-90009 is a novel cereblon (CRBN) E3 ligase modulator and specifically targets GSPT1 (G1 to S phase transition 1) for proteasomal degradation.
S0095	VL285	VL285 is a potent VHL ligand that degrades HaloTag7 fusion proteins. Cotreatment with excess VL285, the core VHL ligand from which HaloPROTAC3 is derived, is able to significantly reduce HaloPROTAC3 mediated activity to 50% degradation.	Int J Mol Sci, 2024, 25(16)8984 Molecules, 2024, 29(2)482
S0097	(S,R,S)-AHPC (MDK7526)	(S,R,S)-AHPC (MDK7526, VH032-NH2, VHL ligand 1) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC is potential useful for the targeted degradation of the androgen receptor. (S,R,S)-AHPC can be connected to the ligand for protein such as BCR-ABL1 by a linker to form PROTACs such as GMB-475. GMB-475 induces the degradation of BCR-ABL1 with IC50 of 1.11 μM in Ba/F3 cells.
S0345	Smurf1-IN-A01	Smurf1-IN-A01 can inhibit Smurf1-mediated Smad1/5 degradation and accelerate BMP-2 signal responsiveness with a Kd of 3.664 nM.
S8449	VH298	VH298 is a potent VHL (Von Hippel-Lindau, the E3 ligase) inhibitor that stabilizes HIF-α. VH298 blocks the VHL:HIF-α interaction with Kd of 90 nM in isothermal titration calorimetry (ITC) and 80 nM in a competitive fluorescence polarization assay. VH-298 can be used in PROTAC technology.	Cell Rep, 2025, 44(6):115800 Eur J Med Chem, 2024, 268:116202
E0071	MuRF1-IN-1	MuRF1-IN-1 is a muscle ring finger protein-1 (MuRF1) inhibitor that attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia.
E1937	PT-179	PT-179, an orthogonal Thalidomide derivative targets cereblon without causing off-target degradation effects. PT-179 specifically binds CRBN, forms a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediates the degradation of the tagged protein.
S8979	THAL-SNS-032	THAL-SNS-032 is a selective Cyclin-dependent kinase 9 (CDK9) degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to that binds the E3 ubiquitin ligase Cereblon (CRBN).	Gastroenterology, 2024, S0016-5085(24)00062-3
E0351	NSC232003	NSC232003 is a highly potent and cell-permeable UHRF1 inhibitor that binds to the 5mC binding pocket of the SRA domain of UHRF1. NSC232003 modulates DNA methylation in a cellular context.
E1678	SPOP-i-6lc	SPOP-i-6lc is a selective speckle-type POZ protein (SPOP) E3 ubiquitin ligase inhibitor with IC50 of 2.1 μM and 3.5 μM, in A498 and OS-RC-2 cell lines, respectively. In vitro, It suppresses viability and proliferation of A498 and OS-RC-2 kidney cancer cell lines.
E1087	5-amino-2,4-dimethylpyridine (5A-DMP)	5-amino-2,4-dimethylpyridine (5A-DMP) is a novel tandem Tudor domain (TTD)-binding compound that inhibits the full-length UHRF1:LIG1 interaction in Xenopus egg extracts.
S2678	NSC 207895	NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.	PLoS One, 2024, 19(1):e0295629 Front Oncol, 2021, 11:582511 Genes Dev, 2020, 34(7-8):526-543
S1061	Nutlin-3	Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.	Cancer Discov, 2025, 15(1):69-82 Biomed Rep, 2025, 22(4):65 Nat Biotechnol, 2024, 10.1038/s41587-024-02172-9
S1172	Serdemetan (JNJ-26854165)	Serdemetan (JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.	Elife, 2025, 14e75393 Signal Transduct Target Ther, 2022, 7(1):97 iScience, 2021, 24(9):103080
S8975	Mezigdomide (CC-92480)	Mezigdomide (CC-92480) is a novel protein degrader and a cereblon E3 ligase modulator (CELMoD) that has anti-myeloma activity.	Nat Commun, 2024, 15(1):8885 Mol Cancer Ther, 2023, 22(5):659-666 Mol Cancer Ther, 2023, 22(5):659-666
S8300	CC-885	CC-885 is a novel cereblon (CRBN) modulator. CC-885 selectively promotes CRBN- and p97-dependent PLK1 ubiquitination and degradation.	Sci Rep, 2025, 15(1):2384
E1300	SJ6986	SJ6986 is a CRBN modulator and specifically degrades GSPT1/2, with a DC50 of 2.1 nM (Dmax 99%) for GSPT1.
E5839^New	OICR-8268	OICR-8268 is a potent, reversible and in-cell active DCAF1 ligand. It significantly binds to DCAF1 WDR domain with an Kd value of 38 nM. It serves as a promising starting point for developing chemical handles for DCAF1-based PROTACs targeting selective protein degradation as well as cancer therapeutics.
F0528^New	Ubiquitin (linkage-specific Lys 63) Rabbit mAb	K63-linkage Specific Polyubiquitin,Ubiquitin (linkage-specific K63),Ub-K63
F2194^New	Cullin 1/CUL-1 Rabbit mAb	CUL1,CUL-1,Cullin 1,Cullin 1/CUL-1
F1516^New	PIAS3 Rabbit mAb
F1233^New	KLHL12 Mouse mAb
E1957^New	NX-1607	NX-1607 (Cbl-b-IN-3) is an oral inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), which is an E3 ubiquitin ligase and a key regulator of T, NK, and dendritic cell activation and suppresses their anti-tumor functions. NX-1607 enhances antigen recall, reduces T cell exhaustion, and increases cytokine production in response to T cell receptor stimulation, thereby counteracting suppressive signals from the tumor microenvironment.
E5844^New	NSC2805	NSC2805 is a potent inhibitor of WWP2 ubiquitin ligase with an IC50 of 0.38 μM. It is used in cancer research for studying WWP2-associated pathways.
E1847^New	GBD-9	GBD-9 is a double-mechanism efficient degrader of BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). GBD-9 acts both as a PROTAC molecule to induce the degradation of BTK and as a molecular glue to degrade GSPT1.It exhibits anti-proliferative effects, inhibiting cancer cell survival.
E5839^New	OICR-8268	OICR-8268 is a potent, reversible and in-cell active DCAF1 ligand. It significantly binds to DCAF1 WDR domain with an Kd value of 38 nM. It serves as a promising starting point for developing chemical handles for DCAF1-based PROTACs targeting selective protein degradation as well as cancer therapeutics.
E5877^New	LYG-409	LYG-409 is a potent, selective, and orally bioavailable degrader of GSPT1, with a DC50 of 7.87 nM. It exhibits strong antiproliferative activity in KG-1 cells with an IC50 of 9.50 nM and demonstrates significant antitumor efficacy in vivo in models of acute myeloid leukemia and prostate cancer.

Choose Selective E3 Ligase Inhibitors

Tags: Ubiquitin ligase inhibitor | E3 ligase inhibitor